Keyphrases
Randomized Trial
100%
Graft-versus-host Disease (GvHD)
100%
Meta-analysis
100%
Systematic Meta-analysis
100%
Randomized Clinical Trial
100%
Frontline Treatment
100%
Confidence Interval
66%
Relative Risk
66%
Generic Immunosuppression
66%
Infliximab
33%
Inclusion Criteria
33%
Prednisone
33%
Response Rate
33%
Immunosuppression
33%
Overall Survival
33%
Targeted Therapy
33%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Control Arm
33%
Common Complications
33%
Beneficial Effects
33%
Mycophenolate Mofetil
33%
Anti-interleukin-1
33%
Random-effects Meta-analysis
33%
Limited Samples
33%
Non-immune
33%
Immune Signaling
33%
Prognostic Biomarker
33%
Novel Form
33%
Predictive Biomarker
33%
Soluble interleukin-2 Receptor (sIL-2R)
33%
Immunotoxin
33%
Antithymocyte Globulin
33%
Immunomodulatory Therapy
33%
Daclizumab
33%
Early Termination
33%
High-dose Steroids
33%
Treatment Other
33%
Aggregate Data Meta-analysis
33%
Medicine and Dentistry
Arm
100%
Immunosuppressive Treatment
100%
Meta-Analysis
100%
Systematic Review
100%
Randomized Clinical Trial
100%
Acute Graft Versus Host Disease
100%
Biological Marker
33%
Overall Survival
33%
Targeted Therapy
33%
Cell Transplantation
33%
Drug Megadose
33%
Thymocyte Antibody
33%
Immunomodulation
33%
Prednisone
33%
Immunity
33%
Immunotoxin
33%
Daclizumab
33%
Infliximab
33%
Inolimomab
33%
Interleukin 2 Receptor Antibody
33%
Hematopoietic Cell
33%
Mycophenolate Mofetil
33%
Immunology and Microbiology
Immunosuppression
100%
Arm
100%
Acute Graft Versus Host Disease
100%
Hematopoietic Cell
33%
Drug Megadose
33%
Overall Survival
33%
Immunity
33%
Cell Transplantation
33%
Sample Size
33%
Prednisone
33%
Immunomodulation
33%
Prognostic Biomarker
33%
Anti-Thymocyte Globulin
33%
CD5
33%
Daclizumab
33%
Infliximab
33%
Immunotoxin
33%
Interleukin 2 Receptor Antibody
33%
Inolimomab
33%
Mycophenolate Mofetil
33%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
100%
Randomized Clinical Trial
100%
Infliximab
33%
Prednisone
33%
Biological Marker
33%
Overall Survival
33%
Thymocyte Antibody
33%
Immunotoxin
33%
Immunomodulation
33%
Daclizumab
33%
Inolimomab
33%
Interleukin 2 Receptor Antibody
33%
Mycophenolate Mofetil
33%